Yahoo Finance

Cancer Cachexia Pipeline Market Research Report 2025: Insights for 15+ Companies and 20+ Drug Candidates - Innovation in Drug Delivery Methods and Biologic Formulations

Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The "Cancer Cachexia - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering. The "Cancer Cachexia - Pipeline Insight, 2025" report ...
Business Insider

Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference

Patients treated with ART27.13 showed consistent improvements in weight, lean body mass, and activity While clinical benefits were observed in all treated cohorts, the best outcomes in CAReS were ...
BioSpace

Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop ...
Seeking Alpha

Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (ARTL) (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to ...
Benzinga.com

Artelo Biosciences Drug Helps Cancer Patients Regain Weight, Eyes Licensing Deal

Artelo Biosciences, Inc. (NASDAQ:ARTL) on Wednesday released interim results from its Phase 2 Cancer Appetite Recovery Study (CAReS) trial with ART27.13, the company’s peripherally acting cannabinoid ...